Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Inga Benson

Nurse Practitioner Winston Salem, NC Nurse Practitioner

NPI 1699932293 CMS profile 10790409

3333 Silas Creek Pkwy, Winston Salem, NC 27103

Open in the dashboard

General payments

$4,948

252 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Inga Benson of Winston Salem, NC is reported in the CMS Open Payments database as having received $4,948 across 252 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $651 31
2024 General $1,129 52
2023 General $910 44
2022 General $954 53
2021 General $1,303 72

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Inga Benson
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Inga Benson were reported at $651. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Inga Benson Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,303 $135 $40–$426 $132
2022 $954 $152 $48–$470 $149
2023 $910 $166 $54–$529 $160
2024 $1,129 $173 $55–$556 $164
2025 $651 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Pfizer Inc. $782 43 payments
  2. AbbVie, Inc. $707 31 payments
  3. Novartis Pharmaceuticals Corporation $571 35 payments
  4. Janssen Pharmaceuticals, Inc $551 28 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $458 22 payments
  6. Merck Sharp & Dohme Corporation $323 18 payments
  7. AstraZeneca Pharmaceuticals LP $315 22 payments
  8. Novo Nordisk Inc $292 5 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $172 8 payments
  10. E.R. Squibb & Sons, L.L.C. $169 10 payments
  11. Other $607 30 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,948 252 payments
Products named General payments · program years 2021–2025
  1. ELIQUIS $782 43 payments
  2. DALVANCE $707 31 payments
  3. XARELTO $551 28 payments
  4. PAXLOVID $451 24 payments
  5. NURTEC ODT $346 18 payments
  6. JARDIANCE $325 17 payments
  7. LOKELMA $300 21 payments
  8. ENTRESTO Cardiovascular $272 18 payments
  9. LEQVIO $262 15 payments
  10. ENTRESTO Cardiology/Vascular Diseases $249 15 payments
  11. Other $2,636 138 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$20,898

Medicare's payments for the services billed

Medicare patients

98

Average age 74

Services billed

356

26 women, 72 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Ischemic heart disease 72%
Arthritis 55%
Chronic kidney disease 53%
Atrial fibrillation 43%
Heart failure 38%
Depression 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • PFIZER INC. $66
  • E.R. Squibb & Sons, L.L.C. $51
$117 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $107
$107 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $88
$88 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $58
$58 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $58
$58 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

252 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record